{"doi":"10.1007\/s11095-007-9328-y","coreId":"135812","oai":"oai:bradscholars.brad.ac.uk:10454\/3813","identifiers":["oai:bradscholars.brad.ac.uk:10454\/3813","10.1007\/s11095-007-9328-y"],"title":"Determination of the Relative Bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance Manufactured by supercritical fluids and micronization","authors":["Richardson, Catherine H.","De Matas, Marcel","Hosker, K.","Mukherjee, R.","Wong, Ian","Chrystyn, H."],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2007","abstract":"NoPurpose  The relative lung bioavailability of salbutamol sulfate particles produced using supercritical fluids (SEDS\u00bf) and delivered by dry powder inhaler (DPI) was compared with the performance of a conventional micronized drug DPI using the same device design (Clickhaler\u00bf, Innovata Biomed). \\ud\nMaterials and Methods  Twelve healthy volunteers and 11 mild asthmatic patients completed separate four-way randomised cross-over studies, assessing the relative bioavailability of salbutamol sulfate (urinary excretion method), formulated as SEDS\u00bf particles (three batches) and micronized particles (Asmasal\u00bf inhaler, UCB Pharma Ltd). Post-treatment improvements in patient lung function were assessed by measuring FEV1. Physicochemical evaluation of the three SEDS\u00bf batches revealed inter-batch differences in particle size and shape. \\ud\nResults  There was no significant difference in the relative lung bioavailability of salbutamol and its bronchodilator response between the best performing SEDS\u00bf formulation and the Asmasal\u00bf inhaler in volunteers and patients, respectively. SEDS\u00bf salbutamol sulfate showing wafer like morphology gave greater fine particle dose, relative lung bioavailability and enhanced bronchodilation compared to other SEDS\u00bf batches containing elongated particles. \\ud\nConclusions  Active Pharmaceutical Ingredient (API) manufactured using supercritical fluids and delivered by DPI can provide similar lung bioavailability and clinical effect to the conventional micronized commercial product. Product performance is however notably influenced by inter-batch differences in particle characteristics","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":null,"rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:bradscholars.brad.ac.uk:10454\/3813<\/identifier><datestamp>\n                2016-08-18T17:12:06Z<\/datestamp><setSpec>\n                com_10454_152<\/setSpec><setSpec>\n                col_10454_6342<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nDetermination of the Relative Bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance Manufactured by supercritical fluids and micronization<\/dc:title><dc:creator>\nRichardson, Catherine H.<\/dc:creator><dc:creator>\nDe Matas, Marcel<\/dc:creator><dc:creator>\nHosker, K.<\/dc:creator><dc:creator>\nMukherjee, R.<\/dc:creator><dc:creator>\nWong, Ian<\/dc:creator><dc:creator>\nChrystyn, H.<\/dc:creator><dc:subject>\nDry powder inhalers<\/dc:subject><dc:subject>\nFine particle dose<\/dc:subject><dc:subject>\nRelative lung bioavailability<\/dc:subject><dc:subject>\nSupercritical fluids<\/dc:subject><dc:subject>\nUrinary salbutamol<\/dc:subject><dc:description>\nNo<\/dc:description><dc:description>\nPurpose  The relative lung bioavailability of salbutamol sulfate particles produced using supercritical fluids (SEDS\u00bf) and delivered by dry powder inhaler (DPI) was compared with the performance of a conventional micronized drug DPI using the same device design (Clickhaler\u00bf, Innovata Biomed). \\ud\nMaterials and Methods  Twelve healthy volunteers and 11 mild asthmatic patients completed separate four-way randomised cross-over studies, assessing the relative bioavailability of salbutamol sulfate (urinary excretion method), formulated as SEDS\u00bf particles (three batches) and micronized particles (Asmasal\u00bf inhaler, UCB Pharma Ltd). Post-treatment improvements in patient lung function were assessed by measuring FEV1. Physicochemical evaluation of the three SEDS\u00bf batches revealed inter-batch differences in particle size and shape. \\ud\nResults  There was no significant difference in the relative lung bioavailability of salbutamol and its bronchodilator response between the best performing SEDS\u00bf formulation and the Asmasal\u00bf inhaler in volunteers and patients, respectively. SEDS\u00bf salbutamol sulfate showing wafer like morphology gave greater fine particle dose, relative lung bioavailability and enhanced bronchodilation compared to other SEDS\u00bf batches containing elongated particles. \\ud\nConclusions  Active Pharmaceutical Ingredient (API) manufactured using supercritical fluids and delivered by DPI can provide similar lung bioavailability and clinical effect to the conventional micronized commercial product. Product performance is however notably influenced by inter-batch differences in particle characteristics.<\/dc:description><dc:date>\n2009-11-02T11:44:03Z<\/dc:date><dc:date>\n2009-11-02T11:44:03Z<\/dc:date><dc:date>\n2007<\/dc:date><dc:type>\nArticle<\/dc:type><dc:type>\nNo full-text available in the repository<\/dc:type><dc:identifier>\nRichardson, C.H., De Matas, M., Hosker, K. and Mukherjee, R. et al. (2007). Determination of the Relative Bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance Manufactured by supercritical fluids and micronization.  Pharmaceutical Research. Vol. 24, No. 1, pp. 2008-2017.<\/dc:identifier><dc:identifier>\n900159540<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/10454\/3813<\/dc:identifier><dc:language>\nen<\/dc:language><dc:relation>\nhttp:\/\/dx.doi.org\/10.1007\/s11095-007-9328-y<\/dc:relation>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":null,"language":null,"relations":["http:\/\/dx.doi.org\/10.1007\/s11095-007-9328-y"],"year":2007,"topics":["Dry powder inhalers","Fine particle dose","Relative lung bioavailability","Supercritical fluids","Urinary salbutamol"],"subject":["Article","No full-text available in the repository"],"fullText":null}